The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients

Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients

May 23, 2022 • By Sara Jo Santangelo, PharmD candidate, & Wendy Ramey, BSPharm, RPh, CSP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is written. The four immunomodulators mentioned in the guidelines are: baricitinib (Olumiant), tocilizumab (Actemra), tofacitinib (Xeljanz) and sarilumab (Kevzara).1,8 Baricitinib or tocilizumab is preferred over tofacitinib and sarilumab; however, with national and worldwide shortages, and barriers to access, tofacitinib and sarilumab are listed as alternatives.

You Might Also Like
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
  • Tocilizumab Begins Clinical Trial for COVID-19

Tocilizumab and sarilumab are interleukin-6 (IL-6) antagonists. Endogenous IL-6 is induced by inflammatory stimuli and mediates a variety of immunological responses. Inhibition of IL-6 receptors by tocilizumab or sarilumab leads to a reduction in cytokine and acute phase reactant production. Preventing the release of these immune-activating and/or inflammatory molecules could help reduce inflammation and the cytokine storm associated with increased morbidity and mortality from COVID-19.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In both the REMAP-CAP and RECOVERY trials, tocilizumab was shown to have a benefit on mortality in patients with rapid respiratory decompensation. Baricitinib and tofacitinib are Janus kinase (JAK) inhibitors.2,3 JAK inhibitors have anti-cytokine effects, reducing the release of cytokines. Baricitinib, specifically, has potential antiviral effects, interfering with a virus’ ability to enter and infect susceptible cells. In the COV-BARRIER trial, baricitinib also showed a reduction in mortality among patients with COVID-19 treated with the drug.4 This may explain why baricitinib is the preferred JAK inhibitor in the treatment of COVID-19 patients.

The use of these agents to combat COVID-19 in hospitalized patients created the potential for worldwide shortages of these agents and the possibility of interrupted treatment regimens for patients with rheumatic disease. On Sept. 3, 2021, Genentech released the following statement: “During this time, availability of Actemra will vary. We expect additional intermittent periods of stockouts in the months ahead, especially if the pandemic continues at the current pace.”5

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The website, Genentech, has provided updates on the evolving situation (initially in August 2021) stating that subcutaneous formulations of tocilizumab continue to be available, although it admits to a limited supply.6 Then, most recently in March 2022, Genentech released a statement on the media portion of their website, stating availability of both the intravenous and subcutaneous formulations varies over time and is challenging to predict. 5 An attempt was made to reach Genentech by phone for comment on the status of the tocilizumab shortage. A senior manager for corporate relations, referred us back to the March media statement.

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates, Interprofessional Perspective Tagged With: baricitinib, COVID-19, immunomodulatory agent, Interprofessional Perspective, sarilumab, tocilizumab, Tofacitinib

You Might Also Like:
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
  • Tocilizumab Begins Clinical Trial for COVID-19
  • Pharmacy Team Combats COVID-19 in NYC: Q&A with Mark J. Sinnett, PharmD, FASHP

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)